Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
The effect of inosine, guanosine, and guanosine 5'-monophosphate (GMP) on the antitumor activity of 5'-deoxy-5-fluorouridine (5'-DFUR) was investigated using P388 leukemia and P815 mastocytoma. The antitumor activity of 5'-DFUR was markedly enhanced by coadministration of inosine or guanosine. The increase in lifespan (ILS) of mice treated with 5'-DFUR was augmented by the combination with guanosine or inosine in a dose-dependent fashion, and the maximum ILS was about 160% with the combination, while that in the case of 5'-DFUR alone was only 48% in the P388 leukemia system. The therapeutic ratio (dose at ILSmax/dose at ILS30) of the combination with guanosine or inosine was 333 and 136, respectively, whereas that of 5'-DFUR alone was 3.6. GMP also markedly potentiated the antitumor activity of 5'-DFUR in both P388 leukemia and P815 mastocytoma systems, just as it potentiated the activity of 5-fluorouracil in the latter system. The uric acid level in the serum was elevated after IP injection of guanosine or inosine but the value was much lower in the case of guanosine than in inosine.
D000818:Animals; D004357:Drug Synergism; D005467:Floxuridine / Q000494:pharmacology / Q000627:therapeutic use*; D006150:Guanine Nucleotides / Q000494:pharmacology*; D006151:Guanosine / Q000494:pharmacology*; D006157:Guanosine Monophosphate / Q000494:pharmacology*; D007288:Inosine / Q000494:pharmacology*; D007941:Leukemia P388 / Q000097:blood / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D012515:Mast-Cell Sarcoma / Q000097:blood / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D014527:Uric Acid / Q000097:blood
D006150:Guanine Nucleotides; D005467:Floxuridine; D006151:Guanosine; D014527:Uric Acid; D007288:Inosine; D006157:Guanosine Monophosphate; C025034:doxifluridine